Gut Microbiota in Mood Disorders in Lebanese Population
Status:
Not yet recruiting
Trial end date:
2023-12-29
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the pathophysiological aspects of the role of inflammation and
gut microbiota in mood disorders, in particular in depression, and their therapeutic
implications on a cohort of the Lebanese population. Specific objective: The evaluation of
probiotic intake (CEREBIOME®, Lallemand Health Solutions Inc., Mirabel, Canada) on depressive
patients and the inflammatory state. Evaluate the effect of oral intake of a probiotic agent,
on clinical and plasma inflammatory markers, in a subgroup of target patients versus a
subgroup treated with placebo, in combination with conventional treatment.